• Humana Inc. has already reported second-quarter 2026 results, with revenue of US$40,867 million and net income of US$694 million, while also lowering its full-year 2026 GAAP EPS guidance to at least US$6.52 from at least US$8.36.
• Alongside these results, Humana completed a US$276.13 million share repurchase program and added two experienced executives, Paul Smith and Frederick Crawford, to its Board, potentially influencing future governance and capital allocation decisions.
• With Humana pairing strong quarterly earnings with a reduced full-year EPS outlook, we’ll examine how this guidance reset affects its investment narrative.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

Humana Investment Narrative Recap

To own Humana, you need to believe its Medicare Advantage focus, CenterWell expansion and tech investments can support earnings, even as regulation and medical cost trends remain key swing factors. The lowered 2026 GAAP EPS guidance to at least US$6.52 is a reminder that the near term earnings reset is front and center, while the biggest risk right now is how policy decisions and Stars outcomes translate into future profitability. The latest news does not fundamentally change that risk, but it sharpens attention on it.

Against that backdrop, the most relevant update is Humana’s guidance cut following what was, on paper, a solid second quarter, with revenue of US$40,867 million and net income of US$694 million. This contrast between strong reported results and a lower full year outlook matters for anyone focused on near term earnings as a catalyst, especially given ongoing uncertainty around Star ratings, medical cost trends and the timing of margin improvement in Medicaid and CenterWell.

Yet beneath the headline guidance cut, investors should also be aware that...

Humana's narrative projects $183.5 billion revenue and $2.9 billion earnings by 2029.

Uncover how Humana's forecasts yield a $308.33 fair value, a 18% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming revenue of about US$129.7 billion and earnings of roughly US$2.4 billion by 2028, so this guidance reset may push their Medicare Advantage margin concerns even further, and you may find that their more pessimistic view of compressed reimbursement and tighter profitability now feels closer to the center of the debate.

Explore 5 other fair value estimates on Humana - why the stock might be worth 43% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Humana research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.